Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of trabectedin + pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in relapsed ovarian cancer
2004-005276-16Phase 3Completed
- Sponsor
- PharmaMar
- Start
- Aug 2005
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trabectedin, pegylated liposomal doxorubicin in ovarian cancer, sponsored by PharmaMar. Started Aug 2005; status: completed.
02
Drugs
trabectedinpegylated liposomal doxorubicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2004-005276-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005276-16.